30241-46-4Relevant articles and documents
Half-sandwich iridiumIII complexes with pyrazole-substituted heterocyclic frameworks and their biological applications
Gajera, Sanjay B.,Mehta, Jugal V.,Thakor, Parth,Thakkar, Vasudev R.,Chudasama, Piyushkumar C.,Patel, Jagdish S.,Patel, Mohan N.
, p. 9968 - 9980 (2016)
Low-spin IrIII organometallic half-sandwich complexes of type [(η5-C5Me5)Ir(XY)Cl]+ (XY = bipyrazoles (4a-4b)/pyrimidin-2-amines (5a-5b)/triazolo[1,5-a]pyrimidines (6a-6b)) have been synthesized and characterized. All the newly synthesized compounds have been evaluated for their DNA binding properties with calf thymus (CT DNA), which revealed enhancement in the binding constant (Kb) of the complexes. The compounds bearing an imidazole substituent proved to be better binders than compounds containing a phenoxy linkage. Molecular docking attests that π-π stacking interactions have been observed between the receptor and the compounds. Furthermore, the observed DNA cleavage potency has been ascribed to a multitarget mechanism of action of these compounds. Intriguingly, the chelation of ligands with IrIII led to a remarkable enhancement of antibacterial activity against the arbitrarily selected two Gram +ve and three Gram -ve bacterial strains. The complexes of triazolo[1,5-a]pyrimidines proved to be the most cytotoxic compounds towards brine shrimp and S. pombe cells compared to pyrazole-containing heterocyclic frameworks. All complexes showed potent cytotoxicity as compared to the ligands, with IC50 values ranging from 78 to 234 μM toward A549 human lung cancer cells. The potency of the compounds toward these cancer cells was in the order pyrimidin-2-amines > bipyrazoles > triazolopyrimidines.
Novel cytotoxic oxovanadium(IV) complexes: Influence of pyrazole-incorporated heterocyclic scaffolds on their biological response
Gajera, Sanjay B.,Mehta, Jugal V.,Kanthecha, Darshana N.,Patel, Ravi R.,Patel, Mohan N.
, (2017)
Homoleptic VOIV complexes with bidentate heterocycles, namely bipyrazole/pyrimidin-2-amine/triazolopyrimidine derivatives, are novel square pyramidal oxovanadium(IV) complexes. Their identities have been established using physicochemical techni
Design, synthesis, and biological evaluation of novel benzimidazole derivatives as sphingosine kinase 1 inhibitor
Khairat, Sarah H. M.,Omar, Mohamed A.,Ragab, Fatma A. F.,Roy, Sonam,Turab Naqvi, Ahmad A.,Abdelsamie, Ahmed S.,Hirsch, Anna K. H.,Galal, Shadia A.,Hassan, Md. Imtaiyaz,El Diwani, Hoda I.
, (2021/06/17)
Sphingosine kinase 1 (SphK1) has emerged as an attractive drug target for different diseases. Recently, discovered SphK1 inhibitors have been recommended in cancer therapeutics; however, selectivity and potency are great challenges. In this study, a novel series of benzimidazoles was synthesized and evaluated as SphK1 inhibitors. Our design strategy is twofold: It aimed first to study the effect of replacing the 5-position of the benzimidazole ring with a polar carboxylic acid group on the SphK1-inhibitory activity and cytotoxicity. Our second aim was to optimize the structures of the benzimidazoles through the elongation of the chain. The enzyme inhibition potentials against all the synthesized compounds toward SphK1 were evaluated, and the results revealed that most of the studied compounds inhibited SphK1 effectively. The binding affinity of the benzimidazole derivatives toward SphK1 was measured by fluorescence binding and molecular docking. Compounds 33, 37, 39, 41, 42, 43, and 45 showed an appreciable binding affinity. Therefore, the SphK1-inhibitory potentials of compounds 33, 37, 39, 41, 42, 43, and 45 were studied and IC50 values were determined, to reveal high potency. The study showed that these compounds inhibited SphK1 with effective IC50 values. Among the studied compounds, compound 41 was the most effective one with the lowest IC50 value and a high cytotoxicity on a wide spectrum of cell lines. Molecular docking revealed that most of these compounds fit well into the ATP-binding site of SphK1 and form hydrogen bond interactions with catalytically important residues. Overall, the findings suggest the therapeutic potential of benzimidazoles in the clinical management of SphK1-associated diseases.
New pyrazolyl-dibenzo[b,e][1,4]diazepinones: room temperature one-pot synthesis and biological evaluation
Brahmbhatt, Gaurangkumar C.,Sutariya, Tushar R.,Atara, Hiralben D.,Parmar, Narsidas J.,Gupta, Vivek K.,Lagunes, Irene,Padrón, José M.,Murumkar, Prashant R.,Yadav, Mange Ram
, p. 355 - 377 (2019/06/13)
Abstract: Several new (5-aryloxy-pyrazolyl)- and (5-aryl/olefin-sulfanyl-pyrazolyl)-dibenzo[b,e] [1,4] diazepinone scaffolds have been synthesized, by assembling 5-substituted 3-methyl-1-phenyl-pyrazole-4-carbaldehydes of varied nature with different cycl
Green method for the synthesis of chromeno[2,3- C ]pyrazol-4(1 H)-ones through ionic liquid promoted directed annulation of 5-(aryloxy)-1 H -pyrazole-4-carbaldehydes in aqueous media
Li, He,Liu, Chenjiang,Zhang, Yonghong,Sun, Yadong,Wang, Bin,Liu, Wenbo
, p. 932 - 935 (2015/03/30)
The first classical heterocyclic ionic liquid (IL) promoted C-H bond oxidant cross-coupling reaction for the intramolecular annulation of 5-(aryloxy)-1H-pyrazole-4-carbaldehydes to chromeno[2,3-c]pyrazol-4(1H)-ones has been disclosed. The promoter 1,3-dibutyl-1H-benzo[d][1,2,3]triazol-3-ium bromide can be easily recycled and reused with the same efficacies for at least five cycles in aqueous medium. The strategy works smoothly and provides an applicable protocol to construct a wide range of products.
Design, synthesis, and antibacterial evaluation of new Schiff's base derivatives bearing nitroimidazole and pyrazole nuclei as potent E. coli FabH inhibitors
Sangani, Chetan B.,Makwana, Jigar A.,Duan, Yong-Tao,Tarpada, Umesh P.,Patel, Yogesh S.,Patel, Ketan B.,Dave, Vivek N.,Zhu, Hai-Liang
, p. 10137 - 10149 (2016/01/12)
New Schiff's base derivatives 5a-j have been synthesized by reaction between 5-aryloxypyrazole-4-carbaldehydes 3a-j and 2-(2-methyl-5-nitro-1Himidazol- 1-yl)acetohydrazide 4 in the presence of nickel (II) nitrate as a catalyst in ethanol at room temperatu
Synthesis and evaluation on anticonvulsant activities of pyrazolyl semicarbazones
Deng, Xian-Qing,Song, Ming-Xia,Yu, Hai-Hong
, p. 8234 - 8238 (2015/02/02)
In this paper, a series of 2-[(5-phenoxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-methylene]hydrazine carboxamides were synthesized and evaluated for their anticonvulsant activities using the maximal electroshock method. Their neurotoxicities were determined ap
Design and synthesis of pyrazolyl thiosemicarbazones as new anticonvulsants
Deng, Xian Qing,Song, Ming Xia
, p. 2733 - 2737 (2015/04/22)
A series of pyrazolyl thiosemicarbazone derivatives were synthesized and evaluated for their anticonvulsant activity using the maximal electroshock (MES) method. Interestingly, all compounds prepared showed long duration of protection effect in the MES sc
Synthesis, characterization and catalytic evaluation of BiCl 3-ZrO2 for the synthesis of novel pyrazolyl chalcones
Tarannum, Saima,Siddiqui, Zeba N.
, p. 262 - 273 (2014/08/18)
BiCl3-ZrO2 as an efficient heterogeneous catalyst is prepared by a simple process and characterized by FT-IR, powder XRD, SEM-EDX, XRF and BET surface area analyses. Thermal stability of the catalyst has been examined by DSC-TG analyses. The catalyst is recyclable for several runs preserving its high activity. The catalytic activity of BiCl3- ZrO2 is explained by synthesizing a series of novel pyrazolyl chalcones in excellent yields.
Synthesis and antibacterial evaluation of rhodanine-based 5-aryloxy pyrazoles against selected methicillin resistant and quinolone-resistant Staphylococcus aureus (MRSA and QRSA)
Song, Ming-Xia,Zheng, Chang-Ji,Deng, Xian-Qing,Sun, Liang-Peng,Wu, Yan,Hong, Lan,Li, Ying-Jing,Liu, Yi,Wei, Zhi-Yu,Jin, Ming-Jun,Piao, Hu-Ri
, p. 376 - 385 (2013/03/28)
With an intention to synergize the anti-bacterial activity of 5-aryloxy pyrazole and rhodanine derivatives, eight series of hybrid compounds have been synthesized and evaluated for their antibacterial activity. The majority of the synthesized compounds showed good inhibitory activity against selected methicillin resistant and quinolone-resistant Staphylococcus aureus (MRSA, QRSA) with minimum inhibitory concentration (MIC) values in the range of 1-32 μg/mL. The cytotoxicity test suggests that these compounds exhibited in vitro antibacterial activity at non-cytotoxic concentrations. These studies therefore suggest that rhodanine-based 5-aryloxy pyrazoles are interesting scaffolds for the development of novel Gram-positive antibacterial agents.
